Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Inclusion Criteria:

- Males and females between 18 and 65 years of age, inclusive, who were diagnosed with
migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months
before screening.

- During the 28 day screening period, subjects must adequately complete the headache
eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must
be migraine days.

- Headache eDiary was completed on at least 24 of the 28 days prior to randomization.

Exclusion Criteria:

- Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low
back pain, complex regional pain syndrome).

- Psychiatric conditions that are uncontrolled and/or untreated, including conditions
that are not controlled for a minimum of 6 months prior to screening. Patients with a
lifetime history of psychosis, mania, or dementia are excluded.

- Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons
requiring injections within 4 months prior to screening and during the screening
period.

- History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic
tension-type headache, hypnic headache, cluster headache, hemicrania continua, new
daily persistent headache, or sporadic and familial hemiplegic migraine.

- Receipt of any monoclonal antibody treatment (within or outside a clinical trial)
within 6 months before screening.

- Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.